Physician profile
James W Brown
NPI 1770644957
$25,004.92
in general payments reported to CMS, 2019-2025
67 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,428 · 2020: $3,566 · 2021: $4,785 · 2022: $4,045 · 2023: $3,917 · 2024: $3,239 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,180.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,275.30 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $2,970.71 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $2,830.54 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,951.11 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,556.66 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $1,221.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,145.58 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $739.98 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $675.58 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $561.01 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $489.25 | 2019-2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $458.90 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $458.40 | 2023-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $448.95 | 2021-2025 | |
| Allergan, INC. | $448.90 | 2019-2021 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.